Results 41 to 50 of about 151,327 (305)

Renal neuroendocrine tumors

Indian Journal of Urology, 2009
Neuroendocrine tumors (NETs) are uncommon tumors that exhibit a wide range of neuroendocrine differentiation and biological behavior. Primary NETs of the kidney, including carcinoid tumor, small cell carcinoma (SCC), and large cell neuroendocrine carcinoma (LCNEC) are exceedingly rare.The clinicopathologic features of renal NETs diagnosed at a single ...
Brian R Lane, George Jour, Ming Zhou
openaire   +3 more sources

Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor. [PDF]

, 2012
Pancreatic neuroendocrine tumors (PNETs) are relatively rare tumors that arise in the endocrine cells of the pancreas. Historically, somatostatin analogues have been used in this disease primarily for symptom control and, to a limited extent, disease ...
Devata, Sumana, Kim, Edward J
core   +2 more sources

Intrapancreatic accessory spleen false positive to 68Ga-Dotatoc: case report and literature review [PDF]

, 2019
Background: Intrapancreatic accessory spleen (IPAS) is an uncommon finding of pancreatic mass. Differential diagnosis with pancreatic tumor, especially with non-functional neuroendocrine tumor (NF-NET), may be very hard and sometimes it entails ...
Bellato, V., Caronna, R., Cerasari, S., Chirletti, P., Ciardi, A., Cicconi, S., Feola, T., Lancellotti, F., Muttillo, E. M., Sacco, L.   +9 more
core   +1 more source

A nationwide, multi‐institutional collaborative retrospective study of colorectal neuroendocrine tumors in Japan

Annals of Gastroenterological Surgery, 2021
Aim Neuroendocrine tumors (NETs) are one of the subtypes of neuroendocrine neoplasms and are defined as epithelial neoplasms with predominant neuroendocrine differentiation.
Tatsuro Yamaguchi, Keiichi Takahashi, Kazutaka Yamada, Hiroyuki Bando, Hideo Baba, Masaaki Ito, Kimihiko Funahashi, Hideki Ueno, Shin Fujita, Seiji Hasegawa, Yoshiharu Sakai, Kenichi Sugihara   +11 more
doaj   +1 more source

Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors [PDF]

, 2015
Over the past few years, knowledge regarding the molecular pathology of sporadic pancreatic neuroendocrine tumors (PNETs) has increased substantially, and a number of targeted agents have been tested in clinical trials in this tumor type.
Ahn, Balogh, Bergers, Berruti, Capurso, Capurso, Carew, Castellano, Chamberlain, Chan, Chan, Chen, Clynes, Corbo, Corbo, Couvelard, De Wilde, Di Florio, Di Florio, Di Florio, Fazio, Fendrich, Gaur, Gurung, Han, Heaphy, Heaphy, Hobday, Hopfner, House, Jacinto, Jensen, Jiao, Karnik, Karnik, Komori, Kulke, Laplante, Loewith, Lovejoy, Luzi, Marinoni, Marion-Audibert, Mendel, Meric-Bernstam, Missiaglia, Mocellin, Panzuto, Papouchado, Passacantilli, Perren, Pàez-Ribes, Raymond, Sarbassov, Scoazec, Shah, Shi, Tang, Vinagre, Wang, Yang, Yao, Yuan, Zhang, Zhang   +64 more
core   +1 more source

An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. [PDF]

, 2013
BACKGROUND: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are heterogeneous with respect to biological behaviour and prognosis. As angiogenesis is a renowned pathogenic hallmark as well as a therapeutic target, we aimed to investigate the ...
A Couvelard, A Giatromanolaki, A Rinke, AM Marion-Audibert, AT Dimou, B Terris, D Hanahan, D J Pinato, D O’Toole, DC Metz, DJ Pinato, DJ Pinato, E Raymond, EP Hui, F Panzuto, G Kloppel, HS Kim, I Albrecht, IM Modlin, J LeCouter, J Strosberg, J Zhang, JC Yao, JT Chi, JY Scoazec, K Hirabayashi, K Meeran, K Villaume, M Dal Monte, M Perigny, M Ruscica, MA Maynard, N Martin, N Ngo, P Kuiper, R Dina, R Katoh, R Mentlein, R Ramachandran, R Sharma, S Ezziddin, S T K Toussi, T M Tan, VD Corleto, Y Arvidsson, Y Seo, Y Takahashi, YC Patel   +47 more
core   +2 more sources

Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?

Journal for ImmunoTherapy of Cancer
Immune checkpoint inhibitors (ICIs) revolutionized the management of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers.
Davide Ciardiello, Francesca Spada, Nicola Fazio, Maria Giulia Zampino, Lorenzo Gervaso, Rivadavio Antunes Oliveira, Michele Borghesani, Lorenzo Guidi, Lavinia Benini, Laura Algeri, Chiara Alessandra Cella   +10 more
doaj   +1 more source

Plasma acylated and plasma unacylated ghrelin: useful new biomarkers in patients with neuroendocrine tumors?

Endocrine Connections, 2016
To date, the value of fasting plasma acylated ghrelin (AG) and unacylated ghrelin (UAG) as potential novel biomarkers in patients with neuroendocrine tumors (NETs) is unknown.The aims of this study are to (i) compare fasting AG and UAG levels between ...
Roxanne C S van Adrichem, Aart Jan van der Lely, Martin Huisman, Richard A Feelders, Patric J D Delhanty, Wouter W de Herder, Piet Kramer   +6 more
doaj   +1 more source

Pancreatic tumors imaging: an update [PDF]

, 2016
Currently, ultrasound (US), computed tomography (CT) and Magnetic Resonance imaging (MRI) represent the mainstay in the evaluation of pancreatic solid and cystic tumors affecting pancreas in 80-85% and 10-15% of the cases respectively. Integration of US,
Baccari, Paolo, Cappabianca, Salvatore, D'Andrea, Alfredo, Falcone, Giuseppe, Gravante, Sabrina, Manganaro, Lucia, Palumbo, Barbara, Reginelli, Alfonso, Scialpi, Michele   +8 more
core   +1 more source

Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA

Endocrine Connections, 2023
Background: Updated epidemiological data of neuroendocrine tumors are currently lacking. Thus, we performed epidemiological and survival analyses on a large cohort of patients with neuroendocrine tumors and developed a new nomogram to predict survival.
Peiwen Wu, Dongjie He, Hao Chang, Xiaozhi Zhang   +3 more
doaj   +1 more source